Last reviewed · How we verify

Sofosbuvir/Ledipasvir plus Ribavirin 12W

Iran Hepatitis Network · Phase 3 active Small molecule

Sofosbuvir/Ledipasvir plus Ribavirin 12W is a Direct-acting antiviral Small molecule drug developed by Iran Hepatitis Network. It is currently in Phase 3 development for Chronic hepatitis C virus (HCV) infection, Genotype 1, 2, 3, 4, 5, or 6 HCV infection.

Sofosbuvir/Ledipasvir plus Ribavirin works by inhibiting the HCV NS5B polymerase and NS5A protein, and also inhibiting the HCV RNA-dependent RNA polymerase, leading to the suppression of viral replication.

Sofosbuvir/Ledipasvir plus Ribavirin works by inhibiting the HCV NS5B polymerase and NS5A protein, and also inhibiting the HCV RNA-dependent RNA polymerase, leading to the suppression of viral replication. Used for Chronic hepatitis C virus (HCV) infection, Genotype 1, 2, 3, 4, 5, or 6 HCV infection.

At a glance

Generic nameSofosbuvir/Ledipasvir plus Ribavirin 12W
SponsorIran Hepatitis Network
Drug classDirect-acting antiviral
TargetHCV NS5B polymerase, HCV NS5A protein
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Sofosbuvir is a nucleotide analog inhibitor of the HCV NS5B polymerase, while Ledipasvir is a NS5A inhibitor. Ribavirin is an antiviral medication that works by inhibiting the HCV RNA-dependent RNA polymerase. The combination of these three drugs leads to a synergistic effect, resulting in the suppression of viral replication and the clearance of the virus from the body.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sofosbuvir/Ledipasvir plus Ribavirin 12W

What is Sofosbuvir/Ledipasvir plus Ribavirin 12W?

Sofosbuvir/Ledipasvir plus Ribavirin 12W is a Direct-acting antiviral drug developed by Iran Hepatitis Network, indicated for Chronic hepatitis C virus (HCV) infection, Genotype 1, 2, 3, 4, 5, or 6 HCV infection.

How does Sofosbuvir/Ledipasvir plus Ribavirin 12W work?

Sofosbuvir/Ledipasvir plus Ribavirin works by inhibiting the HCV NS5B polymerase and NS5A protein, and also inhibiting the HCV RNA-dependent RNA polymerase, leading to the suppression of viral replication.

What is Sofosbuvir/Ledipasvir plus Ribavirin 12W used for?

Sofosbuvir/Ledipasvir plus Ribavirin 12W is indicated for Chronic hepatitis C virus (HCV) infection, Genotype 1, 2, 3, 4, 5, or 6 HCV infection.

Who makes Sofosbuvir/Ledipasvir plus Ribavirin 12W?

Sofosbuvir/Ledipasvir plus Ribavirin 12W is developed by Iran Hepatitis Network (see full Iran Hepatitis Network pipeline at /company/iran-hepatitis-network).

What drug class is Sofosbuvir/Ledipasvir plus Ribavirin 12W in?

Sofosbuvir/Ledipasvir plus Ribavirin 12W belongs to the Direct-acting antiviral class. See all Direct-acting antiviral drugs at /class/direct-acting-antiviral.

What development phase is Sofosbuvir/Ledipasvir plus Ribavirin 12W in?

Sofosbuvir/Ledipasvir plus Ribavirin 12W is in Phase 3.

What are the side effects of Sofosbuvir/Ledipasvir plus Ribavirin 12W?

Common side effects of Sofosbuvir/Ledipasvir plus Ribavirin 12W include Fatigue, Headache, Nausea, Diarrhea, Anemia.

What does Sofosbuvir/Ledipasvir plus Ribavirin 12W target?

Sofosbuvir/Ledipasvir plus Ribavirin 12W targets HCV NS5B polymerase, HCV NS5A protein and is a Direct-acting antiviral.

Related